Healthcare / Diagnostics & ResearchNasdaqGS
$1.41
+0.00 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-190.8M · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.8%
↓Gross Margin
33.9%
↓Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+36.0%
FCF CAGR
—
FCF margin
-31.4%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $606.9M · net income $-225.7M · FCF $-190.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $606.9M | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B | $1.44B | $901.9M | $990.3M | $966.0M | $1.12B | $491.7M | $91.1M | $96.5M | $47.0M | $28.0M | $28.5M | $4.4M |
| Net Income | $-225.7M | $-225.7M | $-53.2M | $-188.9M | $-328.4M | $-30.1M | $30.6M | $-314.9M | $-153.0M | $-305.3M | $-48.4M | $-30.0M | $-171.7M | $-114.4M | $-29.0M | $-1.3M | $-18.9M | $-30.1M |
| EBITDA | $-41.3M | $-41.3M | $135.3M | $-65.5M | $-270.8M | $97.5M | $143.1M | $-180.2M | $-73.9M | $-174.3M | $25000.00 | $-56.2M | $-130.9M | $-64.4M | $-27.1M | $-19.4M | $-8.9M | $-21.6M |
| EPS | -0.30 | -0.30 | -0.08 | -0.25 | -0.46 | -0.05 | 0.05 | -0.53 | -0.27 | -0.55 | -0.10 | — | — | — | — | -0.01 | -0.08 | -0.15 |
| Gross Margin | 33.9% | 33.9% | 30.6% | 36.8% | 28.7% | — | — | — | — | — | — | — | — | — | 40.7% | 38.4% | 52.6% | 34.9% |
| Operating Margin | — | — | — | — | — | 1.1% | 4.0% | -30.4% | -17.3% | -28.6% | -8.6% | -20.0% | -160.0% | -82.5% | -79.2% | -82.9% | -39.1% | -501.3% |
| Net Margin | -37.2% | -37.2% | -7.5% | -21.9% | -32.7% | -1.7% | 2.1% | -34.9% | -15.5% | -31.6% | -4.3% | -6.1% | -188.4% | -118.5% | -61.7% | -4.6% | -66.4% | -681.6% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.31 | 0.31 | 0.37 | 0.24 | 0.20 | 0.12 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | — | — | — |
| Current Ratio | 3.61 | 3.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-190.8M | $-190.8M | $-208.5M | $-44.5M | $-119.8M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -17.8% | -17.8% | -3.9% | -13.6% | -21.0% | -1.8% | 1.8% | -19.5% | -8.5% | -16.6% | -2.4% | -1.5% | -20.4% | -13.1% | -16.2% | -0.8% | -82.1% | -95.3% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | — | — | 8.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.83 | 0.83 | 0.75 | 0.48 | 0.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -14.9% | -14.9% | -17.4% | -14.0% | — | 23.6% | 59.1% | -8.9% | 2.5% | -13.6% | 127.3% | 439.6% | -5.6% | 105.2% | 68.1% | -1.8% | 545.0% | — |
| EPS Growth | -275.0% | -275.0% | 68.0% | 45.7% | — | -200.0% | 109.4% | -96.3% | 50.9% | -450.0% | — | — | — | — | — | 87.5% | 46.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.30
Residual
+1.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.